AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

Funding to North American startups surged in the first half of 2025, fueled by investor enthusiasm around artificial ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

LSEG also reported a 78% increase in deals worth more than $10 billion during the first half of 2025, compared to 2024 levels ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

A new mRNA injection turns immune cells into cancer-fighting CAR-T cells — inside the body. Faster, cheaper, and potentially ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.